The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary fibrosis
Publications
Pulmonary fibrosis induced by cyclophosphamide.
The Annals of pharmacotherapy. 2001;35(7-8):894-7
Lung toxicity associated with cyclophosphamide use. Two distinct patterns.
American journal of respiratory and critical care medicine. 1996;154(6 Pt 1):1851-6
Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report.
Oncology. 1983;40(3):174-6
Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide.
British medical journal (Clinical research ed.). 1982;285(6343):696
Interstitial pneumonia after prolonged treatment with cyclophosphamide.
The American review of respiratory disease. 1973;108(1):114-7
Progressive pulmonary fibrosis complicating cyclophosphamide therapy.
Acta medica Scandinavica. 1987;221(4):403-7
Pulmonary, pleural and thoracic changes complicating chemotherapy.
Radiology. 1977;125(3):805-9
Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy.
Cancer. 1979;43(5):1607-12
Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.
The Journal of pediatrics. 1978;92(3):443-6